Can low-molecular-weight heparins improve outcome in patients with cancer?

Cancer Treatment Reviews

Volumn 28, Issue 3, 2002, Pages 151-155

  Thodiyil, Paul ^a   Kakkar, Ajay K ^a,b  

^a Department of Surgical Oncology and Technology ^*  (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cancer; Coagulation proteases; LMWH; Survival; Thrombosis

Indexed keywords

CERTOPARIN; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEINASE;

ADVANCED CANCER; ARTICLE; BLOOD CLOTTING; BRAIN CANCER; BREAST CANCER; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOLOGY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; LONG TERM CARE; LUNG CANCER; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; OUTCOMES RESEARCH; OVARY CANCER; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR CELL; VEIN THROMBOSIS;

EID: 0036622701     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00040-3     Document Type: Article

References (18)

1. Hettiarachchi R, Smorenburg S, Ginsberg J, Levine M, Prins M, Buller H. Do heparins do more than just treat thombosis? The influence of heparins on cancer spread. Thromb Haemostas 1999; 82: 947-952.
2. Geerts W, Heit J, Clagett G, Pineo G, Colwell C, Anderson F, et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S-175S.
3. Haas S, Wolf H, Kakkar A, et al. Prevention of fatal pulmonary embolism and death in elective cancer surgery patients: a substudy comparison of certoparin with unfractionated heparin. Blood 2000; 96, 83b abstract 4039.
4. Breddin H, Hach-Wunderle V, Nakov R, Kakkar V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 626-631.
5. Kakkar A, Kadziola Z, Breddin H, Kakkar V. CORTES cancer substudy. ASH abstract book, 2001.
6. Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989; 42: 805-809.
7. Shen V, Pollack E. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 1980; 73: 841-843.
8. Thodiyil P, Kakkar A. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemostas, 2002, in press.
9. Levitan N, Dowlati A, Remick S, Tahsildar H, Sivinski L, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999; 78: 285-291.
10. Thodiyil P, Hand D, Kakkar A. Differential procoagulant gene expression may explain variation in thromboembolic risks in ovarian and breast cancer. Blood 2001; 98: 445a-446a.
11. von Tempelhoff G-F, Harenberg J, Niemann F, Hommel G, Kirkpatrick C, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-824.
12. Lebeau B, Chastang C, Brechot J, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994; 74: 38-45.
13. Ruf W, Mueller B. Tissue factor in cancer angiogenesis and metastasis. Curr Opin J Hematol 1996; 3: 379-384.
14. Kakkar A, Chinswangwatanakul V, Lemoine N, Tebbutt S, Williamson R. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 1999; 86: 890-894.
15. Taniguchi T, Kakkar A, Tuddenham E, Williamson R, Lemoine N. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998; 58: 4461-4467.
16. Yoshida F, Verrusio E, Mihara H, Oh D, Kwaan H. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 1994; 54: 3300-3304.
17. Even-Ram S, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, et al. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the α v β 5 integrin. J Biol Chem 2001; 276: 10952-10962.
18. Li HL, Ye K, Zhang H, Luo Y, Ren X, Xiong A, et al. Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells. Cell Res 2001; 11: 311-315.